

Next innovations in transcatheter valve interventions: new techniques and new valves

Tullio Palmerini

Alma Mater Studiorum, University of Bologna

Italy


Next generation THV design

- Leaflet technology (valve durability and extension of indication to younger patients)
- Valve performance (better deliverability, reduced rates of PPM and PVL, commissural alignment for better coronary access)
- Pure aortic regurgitation
- Plan for THV in THV

The new is coming from the old

EVOLUT FX SYSTEM

Redesigned Tip for
more dilator like vessel
access




Enhanced Visualization
with radiopaque TAV markers to
identify depth and commissures


Increased Capsule Flexibility to
better accommodate the most challenging
anatomies

Single Spine Shaft
for greater shaft flexibility
and improved deliverability

Optimized Stability Layer for
more predictable deployment




Enhanced stability during deployment




Marker orientation identifies alignment


INITIAL POSITIONING



ANNULAR CONTACT



PREDEPLOYMENT




Sapien X 4

Novel frame and leaflet design

- **Enables adjustable sizing while maintaining valve performance over the deployment diameter range**
- **Maintains high radial strength cobalt chromium balloon-expandable design**

Low frame height and large cells

- **Facilitates future coronary access**



Integrity preservation technology

RESILIA tissue


- **Offers enhanced anti-calcification technology and enables dry storage**
- **Maintains bovine pericardial leaflets matched for thickness and elasticity**

Enhanced PET outer skirt



- **Designed to further minimize PVL**
- **Maintains low profile access**

Resilia tissue valve: integrity preservation technology

Glutaraldehyde Fixation



Glutaraldehyde Storage



Stable-Capping
Permanently blocks free aldehydes



Glycerolization
Glycerol displaces water in the tissue and preserves tissue integrity, which enables dry storage



Glycerolized Tissue

RESILIA Tissue Valve



Sapien Ultra versus Sapien X4

SAPIEN 3 Ultra

4 valve sizes (3 mm increments)



20 mm



23 mm



26 mm




29 mm

SAPIEN X4


3 valve sizes, 16 unique deployment diameters (0.5 mm increments)




Sapien X 4 delivery system



Jena valve for pure aortic regurgitation




Jenavalve Trilogy System – Positioning and Securing in AR Anatomy




Alignment

- Aligns THV with native cusps





Positioning/Anchoring

- Locators “clip” onto native leaflets forming a natural seal and stable securement



Deployment

- Large open cells provide access to low coronaries
- 24 diamond-shaped cells provide annular conformability and sealing



Anteris DurAVR THV




- **Balloon expandable**
- **Short frame height**
- **Large open cell geometry**
- **Delivery system can rotate to achieve commissural alignment**
- **ADAPT: anticalcification tissue process (DNA and glutaraldehyde free)**
- **PET skirt**

Anteris DurAVR THV

Single-piece of bovine pericardium tissue

- Near normal hemodynamic function
- Better leaflet coaptation
- Less leaflet stress



First in Human



Design

Prospective, non-randomised, single-arm, single-centre



Purpose

Evaluate the safety and feasibility of the DurAVR™ THV System



Population



13 subjects with severe symptomatic AS



Follow-up



Clinical, echo, MDCT, and cardiac MRI performed. Follow-up to 1 year.

Healthy Aortic Valve




FD = 10%
FRR = 1%
(n=5)

Post DurAVR THV




FD = 14%
FRR = 4%
(n=5)



Restoration of normal aortic flow

Polymeric valves



- Automated robotic manufacturing
- High reproducibility of manufacturing and lower costs
- Polymeric compounds may be modified to meet the needs of THV (biostability, biocompatibility, leaflet strength, and durability)
- For TAVI, only tested in animal model

Foldax Tria Heart valve: the only one tested in humans



- Surgical valve
- Silicone polyurethane material
- Durability of 16 years at Accelerated Wear Testing models
- Low ex-vivo thrombogenicity (non-human primate AV shunt models)

Conclusions

- **Iteration of aortic THV is progressing relentlessly with new devices coming with longer valve durability and better performance in terms of deliverability, PP implantation, PVL, and better commissure alignment for coronary access.**
- **Polymeric heart valves have the potential of long durability, biostability, biocompatibility, and leaflet strength and therefore clinical trials are needed to prove their safety and efficacy.**